Sosei Heptares Operational Highlights and Consolidated Results for Nine Months ended 30 September 2021

Sosei Heptares Operational Highlights and Consolidated Results for Nine Months ended 30 September 2021

PR Newswire

TOKYO and CAMBRIDGE, England, Nov. 11, 2021

TOKYO and CAMBRIDGE, England, Nov. 11, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operational activities during the third quarter 2021 and reports its consolidated results for the nine months ended 30 September 2021. The full report can be found by clicking here.

Shinichi Tamura, President and CEO of Sosei Heptares, commented: "The third quarter has been a period of continued progress. The fund raising that we completed successfully in July has put us in a strong financial position to drive forward our growth strategy. This has seen us focusing on advancing our inhouse and partnered programs, as well as enhancing our powerful platform for identifying and exploiting new druggable target opportunities, including applying AI-based approaches.

In addition, we continue to invest in our portfolio of muscarinic agonists for schizophrenia and other neurological disorders and engage with potential partners around re-licensing the rights to this exciting portfolio to accelerate its development.

As we approach the end of 2021, we can look back and be proud of the achievements we have made during the year and look forward to continued success in 2022." 

Operational Highlights for Q3 2021

Financial Highlights for the Nine-month Period ended 30 September 2021

*Convenience conversion to US$ at the following rates: YTD 2021: 1US$ =108.86 JPY; YTD 2020: 1US$ =107.57 JPY, 31 Dec 2020: 1US$103.52 JPY; 30 Sept 2021: 1US$ = 111.98 JPY

**Non-IFRS measure

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world's leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

"Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

For more information, please visit https://soseiheptares.com/

LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco

Enquiries:

Sosei Heptares – Media and Investor Relations

Hironoshin Nomura, SVP Investor Relations and Corporate Strategy

+81 (0)3 6679 2178 | Hironoshin.Nomura@SoseiHeptares.com

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures

+81 (0)3 5210 3399 | IR@SoseiHeptares.com

Citigate Dewe Rogerson (for Japanese Media)

Yas Fukuda

+81 (0)3 4360 9234 | Yas.Fukuda@citigatedewerogerson.com 

MEDiSTRAVA Consulting (for International Media)

Mark Swallow, David Dible, Eleanor Perkin

+44 (0)20 7638 9571 | SoseiHeptares@medistrava.com 

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Voltar noticias em Inglês